NEW DELHI: Dr Reddy's Laboratories today said it has launched 'Supamove' cream used for treating pain and inflammation in India.
The cream helps in reducing pain and inflammation in patients with joint pain, arthritis, bursitis, tendinitis and lower back pain, the company said.
"The product has been in-licensed from Cymbiotics Inc. USA and will be available in a 30 gm tube," it added.
The company has also launched another product, Venusia Soft lotion in 75 ml pack, used for providing relief from dry, itchy skin also in-licensed from Cymbiotics Inc.
"This will complete Dr Reddy's treatment basket in the emollient and protective space which already includes Venusia cream, Venusia lotion, Venusia max and Venusia bathing bar," Dr Reddy's said.
The company claimed that current market size of topical non-steroidal anti-inflammatory drugs (NSAID) segment is over Rs 352 crore and emollients and protectives market in India is currently valued at Rs 208 crore, it added.
The Hyderabad-based firm, which had revenues of USD 1.7 billion in FY 11 is present in three business segments- pharmaceutical services and active ingredients, global generics and proprietary products.
Shares of Dr Reddy's were today trading at Rs 1,573 in the after noon trade on BSE, up 0.45 per cent from its previous close.
Success in my Habit
Showing posts with label Dr Reddy's. Show all posts
Showing posts with label Dr Reddy's. Show all posts
Thursday, December 29, 2011
Wednesday, April 20, 2011
Dr Reddy's expands R&D centre in Cambridge
Chennai/Hyderabad: Dr Reddy's Laboratories has opened its newly expanded Chirotech Technology Centre, a purpose-built facility to house its laboratories and offices, at the Cambridge Science Park, UK.
“Being located in this historic university city and in one of the leading European centres for science and innovation makes it the ideal location to expand and develop our research, development and technology capabilities. The facility will be a centre of excellence for chemistry and reinforces our commitment to building a leading edge research organisation to meet the innovation needs of our customers,” GV Prasad, vice chairman and CEO of the company, said in a release.
Dr Reddy’s had acquired the Chirotech R&D facility from Dow Pharma along with its manufacturing facility in Mirfield, UK, in 2008 at $32 million. The additional capacity of 33,000 ft built at the centre helps to house more number of scientists and laboratory facilities. The company has already increased the number of scientists to 40 from the previous 30, according to a company spokesman.
The additional capacity will help facilitate an initial doubling of scientific staff in Chirotech while providing for further capacity additions in future, the company said. It is expected to strengthen core capabilities in biocatalysis and chemocatalysis, build capacities in fast growing segments and allow development of other areas of expertise in chemistry and processing for use in the pharmaceutical industry. The new facility is part of the custom pharmaceutical services business unit of Dr Reddy's and will offer these expanded services to its customers worldwide.
“Being located in this historic university city and in one of the leading European centres for science and innovation makes it the ideal location to expand and develop our research, development and technology capabilities. The facility will be a centre of excellence for chemistry and reinforces our commitment to building a leading edge research organisation to meet the innovation needs of our customers,” GV Prasad, vice chairman and CEO of the company, said in a release.
Dr Reddy’s had acquired the Chirotech R&D facility from Dow Pharma along with its manufacturing facility in Mirfield, UK, in 2008 at $32 million. The additional capacity of 33,000 ft built at the centre helps to house more number of scientists and laboratory facilities. The company has already increased the number of scientists to 40 from the previous 30, according to a company spokesman.
The additional capacity will help facilitate an initial doubling of scientific staff in Chirotech while providing for further capacity additions in future, the company said. It is expected to strengthen core capabilities in biocatalysis and chemocatalysis, build capacities in fast growing segments and allow development of other areas of expertise in chemistry and processing for use in the pharmaceutical industry. The new facility is part of the custom pharmaceutical services business unit of Dr Reddy's and will offer these expanded services to its customers worldwide.
Subscribe to:
Posts (Atom)